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Proteomic analysis of human mesenchymal stromal cell
secretomes: a systematic comparison of the angiogenic
potential
Debora Kehl1, Melanie Generali1, Anna Mallone1, Manfred Heller2,3, Anne-Christine Uldry2,3, Phil Cheng4, Benjamin Gantenbein3,5,6,7,
Simon P. Hoerstrup1,5,8,9 and Benedikt Weber 1,4,5,8,10
Human mesenchymal stromal cell (hMSC) secretomes have shown to inﬂuence the microenvironment upon injury, promoting
cytoprotection, angiogenesis, and tissue repair. The angiogenic potential is of particular interest for the treatment of ischemic
diseases. Interestingly, hMSC secretomes isolated from different tissue sources have shown dissimilarities with respect to their
angiogenic proﬁle. This study compares angiogenesis of hMSC secretomes from adipose tissue (hADSCs), bone marrow (hBMSCs),
and umbilical cord Wharton’s jelly (hWJSCs). hMSC secretomes were obtained under xenofree conditions and analyzed by liquid
chromatography tandem mass spectrometry (LC/MS-MS). Biological processes related to angiogenesis were found to be enriched in
the proteomic proﬁle of hMSC secretomes. hWJSC secretomes revealed a more complete angiogenic network with higher
concentrations of angiogenesis related proteins, followed by hBMSC secretomes. hADSC secretomes lacked central angiogenic
proteins and expressed most detected proteins to a signiﬁcantly lower level. In vivo all secretomes induced vascularization of
subcutaneously implanted Matrigel plugs in mice. Differences in secretome composition were functionally analyzed with monocyte
and endothelial cell (EC) in vitro co-culture experiments using vi-SNE based multidimensional ﬂow cytometry data analysis.
Functional responses between hBMSC and hWJSC secretomes were comparable, with signiﬁcantly higher migration of CD14++
CD16− monocytes and enhanced macrophage differentiation compared with hADSC secretomes. Both secretomes also induced a
more profound pro-angiogenic phenotype of ECs. These results suggest hWJSCs secretome as the most potent hMSC source for
inﬂammation-mediated angiogenesis induction, while the potency of hADSC secretomes was lowest. This systematic analysis may
have implication on the selection of hMSCs for future clinical studies.
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INTRODUCTION
Mesenchymal stromal cells (MSCs) are a heterogeneous popula-
tion of non-clonal cells containing a multipotent stem cell fraction.
Since their introduction for the use in regenerative medicine, the
number of pre-clinical and ﬁrst clinical studies has continuously
increased over the last decades.1 More than 850 registered human
clinicals trials have been performed by September 2018 (Clin-
icalTrial.gov) and these numbers are expected to further increase
in the near future. Initial MSC research focused on the multilineage
differentiation of cells towards desired phenotypes. However, it
has become evident that functional beneﬁts exerted by MSCs
upon transplantation are rather due to the release of paracrine
factors and biologically relevant molecules to the neighboring
diseased or injured tissue.2,3 The MSC secretome inﬂuences the
microenvironment upon injury, promoting cytoprotection, and
tissue repair of the damaged area. These effects are of particular
interest for the treatment of ischemically damaged tissues in
which promoting vascularization and reinstalling perfusion via
angiogenesis is crucial for increasing potential tissue rescue and
thereby preventing ﬁbrosis.
Angiogenic factors released by MSCs include among others
basic ﬁbroblast growth factor (bFGF), vascular endothelial growth
factor (VEGF), transforming growth factor beta (TGF-β), platelet-
derived growth factor (PDGF), angiopoietin-1 (ANG-1), placental
growth factor (PIGF), interleukin 6 (IL-6), and monocyte chemoat-
tractant protein 1 (MCP-1).4 The MSC secretome positively
stimulates angiogenesis in vitro and in vivo4 and the angiogenic
activity can be signiﬁcantly inhibited by neutralizing antibodies
against speciﬁc cytokines, such as VEGF, MCP-1, and IL-6.5 In
addition, exosomes mediate angiogenesis by transferring genetic
material and pro-angiogenic molecules to the damaged areas.6
Interestingly, the tissue origin of MSCs has shown to inﬂuence the
angiogenic potential of the secretome, with different amounts
and concentrations of secreted factors in MSCs from different
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tissue sources. For instance, human adipose tissue derived MSCs
(ADSCs) expressed higher levels of insulin-like growth factor 1
(IGF-1), VEGF-D and IL-8 compared with bone marrow derived
MSCs (BMSCs), whereas other factor such as VEGF-A, bFGF, SDF-1,
and angiogenin were expressed at similar levels.7 In the secretome
of human Wharton’s jelly derived MSCs (WJSCs) more
angiogenesis-related factors were found compared with human
BMSCs, inducing superior in vitro microvasculature formation and
endothelial cell migration.8 Quantitative proteomics revealed an
increased angiogenic proﬁle within the secretome of MSC isolated
from fetal rather than from adult skin.9 Thus, these studies
demonstrate that MSCs isolated from different tissue sources
show dissimilarities with respect to their transcriptional, proteo-
mic, and functional angiogenic proﬁle. However, so far mainly
targeted proteomic approaches have been used with only a
limited number of selected angiogenic proteins analyzed. A
standardized, systematic comparative analysis of the angiogenic
potential of MSC secretomes isolated from different clinically
relevant human MSC (hMSC) sources is missing.
The current study aimed to isolate and fully characterize hMSCs
secretomes from several donors from human adipose tissue
(hADSCs), bone marrow (hBMSCs), and umbilical cord Wharton’s
jelly (hWJSCs) in order to systematically compare their angiogenic
potential. Importantly, hMSC secretomes were obtained under
standardized culture protocols using human platelet lysate (hPL)
to provide clinically feasible xenofree culture conditions. A high-
resolution, two-dimensional liquid chromatography tandem mass
spectrometry (LC-MS/MS) was used to broadly investigate the
proteomic proﬁle of hMSC secretomes. Enrichment analyses
detected the process of angiogenesis as upregulated.
RESULTS
Characterization of hMSCs from different tissue sources
All primary isolated MSC from human adipose tissue (n= 5), bone
marrow (n= 5), and umbilical cord Wharton’s jelly (n= 5) from
independent donors among the tissue sources were cultured in
xenofree proliferation medium based on hPL (for donor char-
acteristics see supplementary Table S1). Multipotent MSC nature
of all 15 cell lines was conﬁrmed by trilineage differentiation into
adipogenic, osteogenic, and chondrogenic lineages (Fig. 1a;
supplementary Fig. S1). No differences were detected in the
differentiation potential of hMSC from different tissue sources.
hADSCs showed higher proliferation abilities compared with
hBMSCs and hWJSCs (Fig. 1b), with signiﬁcantly higher cumulative
population doublings (p < 0.05; one-way ANOVA with Tukey
multiple correction) (Fig. 1c). Multidimensional data obtained by
ﬂow cytometry were processed to generate bidimensional t-SNE
maps (Fig. 1d, e; supplementary Fig. S2). The expression proﬁle of
each marker within each t-SNE graph is described by cumulative
marker expression level plots (Fig. 1d). MSCs from all sources
positively expressed CD73, CD90, and CD105, and only a minimal
proportion of cells were positive for CD14, CD34, and CD45. The
recorded events were subdivided into ﬁve sectors by PhenoGraph
and FlowSom algorithms (Fig. 1e). Events recorded in cluster 5 are
cellular debris. The distribution of the recorded events within the
t-SNE maps is visualized by cumulative density plots of each cell
source (Fig. 1f). hBMSCs appeared to be signiﬁcantly more
abundant in cluster 2 and 3 and signiﬁcantly less abundant in
cluster 1 and 4, compared with hADSCs and hWJSCs (Fig. 1g). No
differences were found for hADSCs and hWJSCs. Cluster 2 and 4
have a higher expression of hMSC markers compared with cluster
1 and 4. These results indicated that the amount of surface
proteins was different among the three hMSC sources and that
hBMSCs had a more pronounced MSC phenotype compared with
hADSCs and hWJSCs.
hMSC CM harvest and quality assessment
The hMSC CM (n= 5 per tissue source) was harvested according
to the outlined workﬂow (supplementary Fig. S3A) at passage 3 to
4. Quality criteria after serum free incubation were deﬁned
according to the (I) cellular viability, and the (II) platelet factor 4
(PF-4) concentration in the hMSC CM (supplementary Fig. S3B–D).
Furthermore, cellular senescence of hMSCs before serum-free
incubation was assessed (supplementary Fig. S4).
Serial dilutions of human platelet lysate allowed the comparison
of the initial amount of PF-4 in normal proliferation medium
(approximately 1 ug/ml) with the one after the CM harvest
procedure (supplementary Fig. S3C). The detection limit of PF-4,
consisting of a 1:3200 dilution, was used as a control for LC/MS-MS
analysis. No signiﬁcant differences were detected in cellular
viability and PF-4 leftover between the three cell sources by one-
way ANOVA (supplementary Fig. S3D). Therefore, the subsequent
results obtained with hMSC CM are not biased by differences in
serum leftover.
β-galactosidase (β-Gal) activity staining showed a tendency of
more β-Gal-positive cells in hADSCs (p= 0.09) and hBMSCs (p=
0.06) compared with hWJSCs by one-way ANOVA with Tukey
multiple comparison, in all cell sources signiﬁcantly lower to the
4 μM doxorubicin control (supplementary Fig. S4A-B). hADSCs
showed enhanced cell cycle activity by signiﬁcantly upregulated
CDKs and corresponding cyclins (see supplementary Fig. S4C for
gene panel). This is also supported by signiﬁcantly higher
expression of MYC, E2F1, and TBX3 or lower expression of
CDC25C compared to hBMSCs (p < 0.01 or p < 0.001) and hWJSCs
(p < 0.01 or p < 0.001) (one-way ANOVA with Tukey multiple
comparison). Reduced levels of tumor suppressors CDKN2A and
CDKN1A demonstrate low activation of effector pathways p16/
pRB and p14/p53/p21. Genes associated to DNA damage response
and repair, such as ATM, NBN, PCNA, CHEK2, TERF2 were highly
upregulated in hADSC compared with hBMSCs (p < 0.01 or p <
0.001) and hWJSCs (p < 0.01 or p < 0.001). This means that despite
uniform cell culture expansion procedures and consistent cell
seeding densities between the three hMSC sources, hADSCs
exhibit higher DNA damage response in combination with a
stronger proliferative phenotype.
Mass spectrometry analysis of hMSC CM reveals biological
processes related to angiogenesis and endothelial cell function as
enriched
The proteome of hMSC CM was analyzed based on the protein
intensities measured by LC/MS-MS (n= 5 per tissue source). All
proteins detected within the hPL leftover control were excluded
from further analysis. A total of 1021 different proteins were
identiﬁed (List of all proteins: supplement L1). Normalized heat
maps revealed a different proteomic proﬁle between the three
hMSC CM sources (Fig. 2a). Four hundred and eighty four proteins
were common to the three hMSC populations, with 22 proteins
being exclusive to hADSC, 40 to hBMSC and 174 to hWJSC
(Fig. 2b). Overall higher protein intensities and more exclusive
proteins were found in hWJSC. The phylogeny of the heat map
conﬁrmed that the CM of hADSC and hBMSC are more related to
each other than with hWJSC (Fig. 2a). When looking at the location
of proteins, 52% were of cytoplasmic origin, 22% nuclear, 13%
from the plasma membrane and 10% from the extracellular space
(Fig. 2c); all of them with different functions (Fig. 2d). Processes
such as ‘endothelial cell differentiation’, ‘regulation of leukocyte
chemotaxis’, ‘extracellular matrix organization’, and ‘angiogenesis’
were shown to be enriched in the overall proteome (Panther
overrepresentation list_all: supplement L1), which are particularly
of interest for the treatment of ischemic diseases. However, in
order to deduce protein functions from gene ontology, additional
enrichment analysis of only extracellular proteins was performed
(Panther overrepresentation list_extracellular: supplement L1). The
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Fig. 1 Characterization of hMSC from adipose tissue, bone marrow and umbilical cord Wharton’s jelly. a Trilineage differentiation of hMSCs (n
= 5 per hMSC tissue source) into adipogenic (left; Oil Red O staining), osteogenic (middle; Alzarin Red S) and chondrogenic (right; Alcian Blue
PAS) lineages. Scale bar= 100 μm. b Proliferation capacities of hMSCs (n= 5 per hMSC tissue source) over 12 days, c showing the cumulative
population doublings of each hMSC source. d All hMSCs (n= 5 per hMSC tissue source) positively expressed CD73, CD90, CD105, and only a
minimal proportion of cells were positive for CD14, CD34 and CD45. Data are visualized by bi-dimensional t-SNE maps generated from
multidimensional ﬂow cytometry data. e Recorded events were subdivided into 5 clusters by PhenoGraph and FlowSom algorithms according
to surface marker expression. The cellular distribution of 5 donors per cell source is f visualized with cumulative density plots and g quantiﬁed
accordingly. Bar graphs present mean ± s.d. (*p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA and Tukey multiple comparison)
D. Kehl et al.
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most relevant biological processes, their related proteins and
interactions are summarized in Fig. 3.
hWJSC CM retains the highest angiogenic proteome
A particular focus was given to proteins involved in ‘angiogenesis’
and ‘endothelial cell function’, given that ‘sprouting angiogenesis’
(including angiogenesis, blood vessel morphogenesis/development,
vascular development) and ‘endothelial cell function’ (including
regulation of apoptosis, proliferation and migration) were found to
be enriched in the hMSC CM. Eighty six angiogenesis-related
proteins were detected in hMSC CM, whereas the phylogeny of the
heat maps showed that hBMSC and hWJSC CM are more closely
related to each other compared with hADSC CM (Fig. 4a). Forty six
angiogenic proteins were common to the 3 hMSC populations, with
2 proteins being exclusive to hADSC, 4 to hBMSC and 7 to hWJSC
(Fig. 4f). However, signiﬁcantly higher protein levels were found in
hWJSC CM compared with hBMSC CM and hADSC CM, displayed by
Venn diagram (Fig. 4g). Here, the numbers represent the amount of
proteins with signiﬁcantly higher intensities, detected by pairwise
student t-test between the hMSC groups. All identiﬁed proteins
were uploaded into String database and evaluated using Cytoscape
to deﬁne their interactions. Figure 4b displays these protein
interactions, where node size/color is based on the
Fig. 2 LC/MS-MS analysis of hMSC CM. a Heat maps (red= expressed, blue= not expressed) and b Venn diagrams represent the total amount
of identiﬁed proteins in hMSC CM (n= 5 per hMSC tissue source), where more exclusive proteins and higher protein intensities were found for
hWJSC CM. Identiﬁed proteins found in all hMSC CM were characterized on their d cellular location and e function
D. Kehl et al.
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‘BetweennessCentrality’ deﬁned by the combined score of String
database. Low values are small sized and orange (color code from
low to high: orange–yellow–green–blue). Proteins not being part of
any interaction are not further discussed. High ranked proteins are
those, which possesses more interactions within the network. AKT1
and FGF2 were highly ranked (blue in Fig. 4b), followed by CTNNB1,
IL-6, NOTCH3, PDGFRB, PXN, VEGF-C (green in Fig. 4b) and ANGPT1,
COL18A1, EFNB2, ENG, JAG1, PAX2, RASA1, TIMP2, WNT5A (yellow in
Fig. 4b). Interestingly, out of this protein selection more crucial
angiogenic proteins were missing in the hADSC CM (displayed in
red, Fig. 4c), followed by hBMSC CM (Fig. 4d) and hWJSC CM
(Fig. 4e). Taken together the LC/MS-MS analysis showed that hWJSC
CM retained a more complete pro-angiogenic network with higher
concentrations of angiogenesis related proteins.
hMSC CM induces migration of classical monocytes and enhances
macrophage differentiation
Immune cells are crucial for the process of angiogenesis, which is
also indicated by the analyzed proteomic proﬁle. The immune cell
response induced by hMSC CM (n= 5 per tissue source) was
tested by migration of hPBMCs from three independent healthy
Fig. 3 Enriched biological processes in hMSC CM. LC/MS-MS data were analyzed on overrepresented biological processes in the extracellular
protein fraction of hMSC CM (n= 5 per hMSC tissue source). The most relevant biological processes, their protein-protein interactions and
corresponding coloring patterns are displayed
D. Kehl et al.
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Fig. 4 The pro-angiogenic proteome of hMSC CM. a Heat map generated based on protein intensities displays hMSC CM proteins involved in
angiogenesis (n= 5 per hMSC tissue source; red= expressed, blue= not expressed). b Interactions of angiogenesis related proteins, where
node size/color depends on the amount of protein interactions. Proteins not found in the according CM are displayed in red, demonstrating
that central pro-angiogenic proteins are missing in c hADSC CM compared to d hBMSC CM and e hWJSC CM. f The protein composition of
hMSC CM and their exclusive proteins demonstrate that hBMSC CM and hWJSC CM are closer related compared to hADSC CM; g however
signiﬁcantly higher protein intensities by pairwise student t-test were found for hWJSC CM
D. Kehl et al.
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donors towards a transwell insert. To assure scalable migration of
hPBMCs, the assay was established using different starting
amounts of hPBMCs and concentrations of MCP-1 (supplementary
Fig. S5A-5B). All results were normalized to the migration induced
by basal DMEM medium. hBMSC CM (p < 0.01) and hWJSC CM (p
< 0.001) demonstrated signiﬁcantly higher monocyte migration
when compared with hADSC CM by one-way ANOVA with Tukey
multiple comparison, while no differences were detected between
the CM of hBMSCs and hWJSC (p= 0.07) (Fig. 5a; supplementary
Fig. 5C). No signiﬁcant lymphocyte migration was detected
compared with the initial population seeded, supporting the
immunomodulatory capacity of hMSC CM (supplementary Fig.
S5D). Migrated monocytes were classiﬁed using ﬂow cytometry
into three subgroups known as classical CD14++ CD16− mono-
cytes, intermediate CD14++ CD16+ monocytes, and non-classical
CD14dim CD16+ monocytes (Fig. 5b). The original seeded hPBMC
population consisted of 93.50 ± 2.94% classical, 2.04 ± 0.62%
intermediate, and 4.51 ± 2.56% non-classical monocytes of total
monocytes analyzed (Fig. 5c). After migration mainly classical
CD14++ CD16+ monocytes were detected.
Next, monocytic Thp-1 cells were analyzed after co-incubation
with either hMSC CM (n= 5 per tissue source), basal DMEM
medium (negative control), or original ex vivo Thp-1 medium
(positive control). The results obtained by multicolor ﬂow
cytometry were computed using dimensionality reduction and
clustering algorithms. Seven cell populations were identiﬁed in
cumulative vi-SNE maps based on the expression levels of key
surface markers (Fig. 5d; supplementary Fig. S6; supplementary
Fig. S7).10 Each of the myeloid population was monitored after co-
incubation and the percentages of events per population (Fig. 5e)
and density distributions analyzed (supplementary Fig. S8). We
observed a signiﬁcant decrease in the classical monocyte
population when the cells were co-incubated with hMSC CM (p
< 0.01) or basal DMEM only (p < 0.01) by one-way ANOVA with
Fig. 5 Immune cell response to hMSC CM. a hMSC CM (n= 5 per tissue source) revealed enhanced migration of monocytes (n= 3 healthy
blood donors), with signiﬁcantly higher migration induced by hBMSC CM and hWJSC CM in comparison to hADSC CM and 5 ng/ml MCP-1
control. b Migrated monocytes were characterized by CD14 and CD16 staining, c demonstrating that hMSC CM mainly induced migration of
classical CD14++ CD16− monocytes, but not of intermediate and non-classical monocytes. d 7 myeloid cell populations were identiﬁed after
co-incubation of monocytic Thp-1 cells and hMSC CM (n= 5 per tissue source) displayed by a bi-dimensional cumulative vi-SNE map. e The
percentages of each cell population were monitored, including f classical monocytes, gmacrophages, and h all (diff.) (plasmacytoid) dendritic
cells. hBMSC CM and hWJSC CM led to a signiﬁcantly higher monocyte to macrophage differentiation in comparison to hADSC CM and basal
DMEM control. Bar graphs present mean ± s.d. (*p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA and Tukey multiple comparison)
D. Kehl et al.
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Tukey multiple comparison (Fig. 5f). However, only co-incubation
with hBMSC CM (p < 0.05) and hWJSC CM (p < 0.05) induced a
signiﬁcant increase of macrophages in the overall population
compared with basal DMEM (Fig. 5g), emphasizing that only these
two CM led to a signiﬁcantly higher monocyte to macrophage
differentiation. All hMSC secretomes signiﬁcantly inhibited den-
dritic cell maturation compared with basal DMEM (p < 0.01 or p <
0.001) (Fig. 5h). Based on these functional results the proteins
detected by LC/MS-MS related to phagocyte, lymphocyte, and
granulocyte regulation, activation and chemotaxis were summar-
ized in supplementary Fig. S9. Signiﬁcantly higher inﬂammation-
related protein levels were found in hWJSC CM compared with
hBMSC and hADSC CM.
hMSC CM shows angiogenic potential in vitro and in vivo
As a proof of concept, the pro-angiogenic potential of hMSC CM
detected by LC/MS-MS was evaluated in vivo by performing a
subcutaneous Matrigel plug assay in mice (Fig. 6a). Compared
with controls, all hMSC secretomes enhanced vascularization of
Matrigel plugs. This was conﬁrmed macroscopically and histolo-
gically by H&E staining (Fig. 6a).
To analyze the pro-angiogenic potential of hMSC CM in vitro,
surface marker expression of CD202b, CD105, CD144, and CD31
were analyzed in HUVECs after co-incubation with either hMSC CM
(n= 5 per tissue source), basal DMEM medium (negative control),
or original EGM-2 medium (positive control). Clustering multi-
dimensional ﬂow cytometry data using FlowSOM deﬁned 4
different cell populations according to the expression levels of
angiogenesis related surface markers (Fig. 6b, c; supplementary
Fig. S10). From the surface antigen expression levels these
populations represent different stages of endothelial cells with a
different angiogenic-related phenotype. Cluster 1 represents a
pro-angiogenic HUVEC phenotype with high expression of all
analyzed surface antigens, followed by cluster 2 with an
intermediate phenotype and clusters 3 and 4 with a low
phenotype. The density distribution of the cells was dependent
on the medium HUVECs were co-incubated with (Fig. 6b). Vi-SNE
maps from each biological sample used to generate cumulative vi-
SNE maps are displayed in supplementary Figs. S11-S12. A
Fig. 6 hMSC secretome is pro-angiogenic in vitro and in vivo. a In vivo Matrigel plug assay demonstrated signiﬁcantly increased
vascularization when using hMSC CM compared to basal medium only. Scale bar= 0.5 cm / H&E= 100 μm. b–d Stimulation of HUVEC with
hMSC CM (n= 5 per tissue source) induces expression of angiogenesis related markers, including CD31, CD105, CD202b, and CD144. b The
density distribution of cells was dependent on the co-incubation medium. Clustering ﬂow cytometry data deﬁned 4 different clusters, c each
with a distinct expression proﬁle. d A signiﬁcantly higher shift towards the pro-angiogenic cluster 1 was found when HUVEC were co-
incubated with hBMSC CM and hWJSC CM. Bar graphs present mean ± s.d. (*p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA and Tukey
multiple comparison)
D. Kehl et al.
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signiﬁcant shift towards cluster 1 was found when the cells were
co-incubated with hMSC CM compared with basal DMEM only. A
signiﬁcantly higher shift towards the pro-angiogenic cluster 1 was
found when HUVEC were co-incubated with hBMSC (p < 0.05) and
hWJSC CM (p < 0.05) compared with hADSC CM by one-way
ANOVA with Tukey multiple comparison (Fig. 6d). In cluster 2 a
higher percentage of total cells were found for hADSC CM
compared with hBMSC CM (p < 0.001) and hWJSC CM (p < 0.01)
(Fig. 6d). These results demonstrate that hBMSC CM and hWJSC
CM induce a more angiogenic HUVEC phenotype in vitro
compared with the pro-angiogenic induction triggered by hADSC
CM. The cellular phenotype of HUVEC after co-incubation with
hBMSC CM and hWJSC CM closer resembled the phenotype
obtained by treatment with original EGM-2 medium.
DISCUSSION
The current study demonstrates how the tissue origin inﬂuences
the proteomic proﬁle of the hMSC secretomes. We observed that
biological processes related to the regulation of leukocyte
chemotaxis, endothelial cell function, and angiogenesis are
overrepresented in the proteomic proﬁle of hMSC CM. However,
our results indicated that the composition and concentration of
angiogenic proteins vary between different hMSC CM sources and
ultimately inﬂuence the provoked functional responses.
hBMSC CM and hWJSC CM retained a higher angiogenic proﬁle
when compared with the hADSC CM. hADSC CM showed a lower
amount of angiogenesis related proteins and expressed most of
them to a signiﬁcantly lower level. Interestingly, hADSC CM lacked
central angiogenic proteins, such as AKT1 and FGF2, compared
with hBMSC CM and hWJSC CM. AKT1 has shown to promote
angiogenesis-related functions of BMSCs in vivo11 and its
overexpression in MSCs from amniotic ﬂuid12 and bone
marrow13,14 supported the repair of ischemic cardiac tissue
in vivo. Also, FGF2 is known as a potent inducer of angiogenesis.15
FGF2 addition has shown to enhance the long-term angiogenic
efﬁcacy of transplanted hADSCs into ischemic tissue16 and induce
the production of MSC-derived extracellular vesicles for vessel
stabilization.17 Interestingly, differences in the angiogenic pro-
teome between hBMSC CM and hWJSC CM were not primarily
based on protein composition, but rather on the amount of the
detected proteins itself. Thirty-seven percent of all angiogenic
proteins were measured in signiﬁcantly higher amounts within the
hWJSC CM compared with hADSC CM and hBMSC CM. Previous
comparative studies have also shown that hWJSC CM possesses
more secreted factors involved in angiogenesis compared with
hBMSC CM.8 Ribeiro et al. proposed that hBMSC CM might be
most potent to reduce oxidative stress, while hWJSC CM and
hADSC CM seem more beneﬁcial in the protection against
excitotoxicity.18 It was also suggested that hWJSCs express more
stemness and growth-related genes, whereas hBMSCs express
more genes involved in skeletal development.19
In accordance with the proteomic proﬁle, weaker responses
towards hADSC CM were functionally conﬁrmed in vitro. hBMSC
CM and hWJSC CM signiﬁcantly enhanced the migration of
classical monocytes and led to signiﬁcantly higher monocyte to
macrophage differentiation. The recruitment of circulating mono-
cytes to post-capillary venules has shown to be essential for
microvascular growth.20 Monocyte-derived macrophages regulate
several steps in the process of angiogenesis, including the
secretion of angiogenesis-promoting paracrine factors, the remo-
deling of the extracellular matrix for capillary sprouting and the
interaction with other cell types such as endothelial cells,
pericytes, and vascular smooth muscle cells.20 It has been
suggested that the monocyte/macrophage inﬁltration and angio-
genesis are spatially correlated20 and that inﬁltrating cells regulate
the patterning of the local ECM degradation, consequently
inﬂuencing the distribution of neovessel formation and their
branch points.21 hBMSC CM and hWJSC CM also induced a
signiﬁcantly stronger angiogenic phenotype of co-cultured
endothelial cell. Angiogenesis initiation by hMSC CM is of
particular interest for the treatment of diseases related to ischemia
or insufﬁcient/abnormal vessel growth. Here, we showed as a
proof of concept that application of hMSC CM can promote
vascularization of in vivo implanted Matrigel plugs in mice.
However, further studies are necessary to directly compare the
angiogenesis potential of the three hMSC CM in vivo, including
the amount of newly formed sprouts, as well as their maturation
state.
Minimal criteria for characterizing multipotent MSCs deﬁned in
2006 by the International Society for Cellular Therapy (ISCT)22 do
not consider potential proteomic and functional differences
between hMSC isolated from different tissue sources. Trilineage
differentiation and MSC surface markers failed to sufﬁciently
phenotype the cellular composition and biological function of
hMSCs in accordance with previous studies.23 These results also
highlight the ongoing discussion about the need for optimized
MSC characterization parameters, with the ultimate goal to enable
comparison across multiple research ﬁelds and clinical studies
involving hMSCs.23 In fact, currently used ISCT criteria produce
heterogeneous, non-clonal cultures of stromal cells containing
multipotent stem cells, committed progenitors, and differentiated
cells.24 We are therefore still far from deﬁning a molecular
signature for hMSCs from different tissue sources, also considering
different percentages of stem cells among donors within the
heterogenous hMSC population. Importantly, patient variability
due to general characteristics (i.e., age, gender etc.) or underlying
health status (i.e., comorbidities, nonsteroidal anti-inﬂammatory
drugs etc.) cannot be excluded in the presented study despite
consistent isolation and characterization procedures. MSCs have
been isolated from independent donors among the different
tissue sources. Although a direct comparison of MSCs derived
from all three tissue sources of the same donor would have been
desirable, this was impossible due to ethical and logistical reasons.
A major challenge of in vitro secretome studies lies in
discriminating proteins that are truly MSC-secreted from those
that are artifacts derived from cell culture media components
(such as serum proteins) or derived from non-physiological
stresses affecting the starving cells. In this regard, hMSC CM
harvest procedures allow for the attachment of serum proteins
that can later be released into the hMSC CM.25 This contamination
with serum proteins might have been neglected in many previous
hMSC secretomes-based studies, which may have led to mislead-
ing scientiﬁc conclusions. Therefore, the presented study for the
ﬁrst time deﬁned remaining serum proteins by the detection of
PF-4 and used a serial dilution of it as a control for the LC/MS-MS
analysis. However, proteins identiﬁed in any of the PF-4 controls
were not included into the analysis. Therefore, some proteins
might have been missed by this procedure as they can be derived
from both, hMSCs and hPL. In particular low concentration
proteins released from hMSCs will overlap with proteins in the hPL
control. Further, intracellular proteins can be detected in the hMSC
CM due to cellular death or leakage. There is now evidence that
some of these proteins can also be released via nonclassical
pathways as vesicles and exosomes and exert extracellular
functions that seem to be different from their intracellular role.25
Considering non-physiological stresses during secretomes harvest,
it has been shown that factors released from apoptotic MSCs can
contribute to the regeneration of ischemic tissues,26,27 but that
senescence also induces changes in the composition of the
secretome and therefore might inﬂuence MSC physiology.28 Sun
et al. highlighted the beneﬁcial immunomodulatory roles of
apoptotic multipotent stem cells by demonstrating that combined
therapy with apoptotic and healthy ADSCs is superior to either
alone.27 However, on the other side replicate senescence in later
passage hMSCs has been associated with reduced clinical
D. Kehl et al.
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outcome in patients with graft-versus-host disease.29 We showed
that despite consistent cell culture procedures, hWJSC exhibit
lower senescence-associated β-Gal activity and hADSCs exhibit
higher DNA damage response in combination with a proliferative
phenotype. This hADSCs phenotype is supported by the fact that
overexpression of oncogenes MYC and E2F1 are known to initiate
a ﬁrst transient hyperproliferation phase with a subsequent DNA
damage response ﬁnally resulting in cellular senescence.30,31 We
believe that the activation of DNA damage response has been
initiated in hADSC, but that the threshold for reaching cellular
senescence and cell cycle arrest has not been reached so far.
These differences might have inﬂuenced the angiogenic potential
of hADSCs, however its causative role cannot be deﬁned with the
current data set.
Overall the presented study describes the cellular origin and
function of all detected proteins and did not only focus on the
extracellular subset. We believe that the complete secretome
needs to be described in order to understand protein interactions
and in vivo functionality. Unlike pharmaceutical treatments that
deliver a single agent, the hMSC secretome provides several
stimulatory and inhibitory bioactive factors at variable concentra-
tions that might sustain physiological kinetics in the local
microenvironment. In ischemic heart diseases, single cytokine
therapy trials have not met expectations suggesting that
processes such as angiogenesis may need simultaneous orches-
tration of multiple factors at different concentrations to act
synergistically.32 High concentrations of single factors can even
lead to the formation of aberrant and leaky vessels, hypotension
and tumor angiogenesis.33 Furthermore, the establishment of
clinical treatments based on hMSC secretome has clear advan-
tages for clinical translation and applicability compared with
currently used autologous or allogenic cell therapies. In particular
when manufacturing costs and logistics, handling, safety and
regulatory aspects of hMSC secretome are considered. The
unlimited supply of the hMSC secretome off-the-shelf without
the need for harvesting autologous patient tissue would
represents a major advantage. So far, there is only a limited
number of ﬁrst in men studies and clinical trials initiated using
MSC secretomes in the ﬁeld of wound healing,34 graft-versus-host
disease,35 hair loss,36,37 multiple sclerosis,38 and alveolar bone
regeneration.39 However, all applications have shown safety
without any severe adverse reactions reported and point towards
a potential clinical use in the future.
In conclusion, we have systematically compared hMSC from
adipose tissue, bone marrow, and umbilical cord Wharton’s jelly in
order to deﬁne which cell source possesses the highest potential
for angiogenesis. A xenofree approach towards generating hMSC
CM and enabling safe clinical translation has been established.
hMSC CM from different tissue origins showed signiﬁcant
functional and proteomic differences with regards to angiogen-
esis. Proteomic results indicate that hWJSC CM might represent
the most potent hMSC source for therapeutic angiogenesis
induction as hWJSC CM showed higher concentrations of
angiogenesis related proteins. Even if the functional responses
between hBMSC CM and hWJSC CM were comparable, the
amount of hBMSC obtained from invasive bone marrow puncture
is limited and susceptible to aging factors, involving the
accumulation of cellular damage, cell death, and senescence.
hWJSCs can be obtained from healthy, young tissue with minimal
ethical concerns. Therefore, the noninvasive harvest, its fetal origin
and unlimited supply as leftover material, supports the highest
therapeutic value of hWJSC secretomes for angiogenesis induc-
tion. In adult patients, our results indicate that hBMSC CM has a
higher potential for angiogenesis when compared with the same
amount of hADSC CM. These differences may thus have
implications on the selection of hMSCs in future clinical studies.
METHODS
hMSC isolation from different human tissues
hMSC from human adipose tissue (n= 5), bone marrow aspirate (n= 5),
and umbilical cord Wharton’s Jelly (n= 5) were isolated from independent
donors among the tissue sources (supplementary Table 1 for hMSC donor
characteristics) and cultured in a humidiﬁed incubator at 5% CO2 at 37 °C
using standard proliferation medium consisting of high-glucose DMEM
(Sigma, Switzerland) supplemented with 10% human platelet lysate (hPL),
1% Glutamax (Gibco, USA), and an antibiotic-antimycotic solution (Sigma,
Switzerland). hPL was obtained from platelet apheresis collection of donors
compliant with local blood donation regulations (Center for Blood
Donation Zurich, Switzerland). Medium changes were done every third
day and passaging was performed using Accustase (Innovative Cell
Technologies Inc., USA).
Adipose tissue (n= 5) obtained from surgically performed liposuction
procedure after written informed consent from the donors was used for
the isolation of hADSCs approved by the cantonal ethics committee Zurich,
Switzerland (KEK-ZH-2010-0476). Adipose tissue was digested using
collagenase type A (Roche Diagnostics GmbH, Switzerland) at 37 °C for
1 h under constant gentle motion. The sample was ﬁltered using a nylon
cell strainer with 70 μm mesh size (BD Bioscience, USA) and separated by
histopaque-1077 density gradient centrifugation (Sigma, Switzerland) for
30min at 600 × g. The interphase was plated in standard proliferation
medium consisting of high-glucose DMEM (Sigma, Switzerland) supple-
mented with 10% human platelet lysate (hPL), 1% Glutamax (Gibco, USA),
and an antibiotic-antimycotic solution (Sigma, Switzerland) for cellular
attachment and growth.
Human bone marrow aspirate (n= 5) was collected in sterile heparinized
tubes (BD Bioscience, USA) after written informed consent from the
patients approved by the cantonal ethics committee Bern, Switzerland. For
isolation of hBMSCs the aspirate was separated by histopaque-1077
density gradient centrifugation for 25min at 800 × g. Subsequently, the
mononuclear cell layer was collected, washed, and plated in standard
proliferation medium.
Human umbilical cords (n= 5) were obtained after full-term births with
written informed consent of the donors approved by the cantonal ethics
committee Zurich, Switzerland (KEK-ZH-2009-0095), and processed for
isolation of hWJSC. Wharton’s jelly (perivascular and intermediate
Wharton’s jelly region) was dissected from the umbilical cord and cut
into small pieces (1 mm2). After letting the tissues adhere to the culture
plate, standard proliferation medium was gently added. Tissue pieces were
removed after a ﬁrst cellular outgrowth could be detected and cells were
harvested for subsequent passaging.
hMSC characterization
Multilineage differentiation was assessed by inducing differentiation to
osteocytes, adipocytes, and chondrocytes as previously described.40 After
3 weeks, cells were ﬁxed in 4% paraformaldehyde/PBS and stained with (I)
2% Alzarin Red S (Sigma, Switzerland), (II) 3 mg/ml Oil Red O (Sigma,
Switzerland) or III) Alcian Blue PAS.
Proliferation was assessed at day 3, 6, 9, and 12. Cells were ﬁxed with
methanol for 10min (Sigma, Switzerland) and stained with 0.1% crystal
violet (Artechemis, Switzerland) for 5 min. After washing and air-drying,
absorbed crystal violet was solubilized with Na-deoxycholate (Sigma,
Switzerland) while being heated at 60 °C for 10min. The absorbance was
recorded at 550 nm using a standard ELISA reader Synergy HT (Bio TEK,
USA). Quantitative data was obtained using a standard curve with serial
dilutions. Generation times (GT) were calculated as previously described.41
hMSCs were characterize on commonly used surface markers CD14,
CD34, CD45, CD73, CD90, and CD105 by ﬂow cytometry. 2.5 × 105 hMSCs
were stained for 20min at 4 °C according to standard procedures with the
antibodies listed in supplementary Table S2. Fifty thousand events were
acquired using a LSR Fortessa (BD Bioscience, USA) and the data sets were
analyzed by FlowJo software (Tree Star, Inc., USA) gating viable and single
cells (for gating strategy see supplementary Fig. S13). Bidimensional t-SNE
maps were generated from multidimensional ﬂow cytometry data sets of
viable and single cells using the open source R platform and the Cytokit
package (http://bioconductor.org). Five thousand events were randomly
selected and clustered using PhenoGraph algorithm (k= 40). PhenoGraph
arranges all events in the multidimensional space according to similarities
in surface marker expression levels and allowed to plot the data in two
dimensions using bi-dimensional visual stochastic neighbor embedding
(vi-SNE) graphs. We used the clustering by FlowSOM and generated t-SNE
graphs to analyze and detect subset differences in MSC marker expression
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proﬁle.42 Each recorded cell is positioned according to surface marker
similarities in separate regions.
hMSC conditioned media harvest and quality assessment
For hMSC secretomes harvest, deﬁned as conditioned media (CM), all
hMSC lines (passage 3 to 4) were cultured until 80% conﬂuence in standard
proliferation medium, washed three times with PBS and starved in serum-
free conditions (basal medium only) for 16 h. Collected CM was ﬁltered
using a 0.2 μm ﬁlter, concentrated using centrifugal ﬁlter units with a 3-
kDA cutoff at 4 °C (Amicon Ultra Centrifugal ﬁlters, Millipore, USA) and
stored at −80 °C for further analysis. Aliquots of stored hMSC CM were
derived from 1 × 106 hMSCs in 0.2 ml. Exact number and viability of starved
cells was obtained using a NucleoCounter NC-200 (CHemoMetec, Den-
mark). Histochemical staining of β-galactosidase (β-Gal) activity (Sigma,
Switzerland) was used to quantify the percentage of senescent cells by the
number of blue, β-Gal-positive cells after incubation under standard
culture conditions and 4 μM doxorubicin (Sigma, Switzerland). In addition,
a qRT-PCR of senescence associated genes was performed using standard
conditions on a QuantStudio 7 ﬂex real-time PCR system (Quiagen,
Switzerland and Applied Biosystems, Thermoﬁsher, USA). GAPDH served as
housekeeping gene to quantify relative stemness expression using the ΔCT
threshold cycle method and calculated with 2−ΔCT. Serum leftover of the
primarily added hPL was assessed by quantitative evaluation of platelet
factor 4 (PF-4), a cytokine uniquely released from activated platelets, using
a multiplex particle-based ﬂow cytometric cytokine assay.43 PF-4 served as
a surrogate marker for the remaining hPL concentration in order to
exclude biases due to differences in the post-starvation hPL content
between different MSC sources.
Mass spectrometry analysis
Proteins of hMSC CM derived from 1 × 106 cells (not concentrated) were
retrieved using 5 μl Strata Clean resin beads per ml of CM (Agilent
Technologies, USA) and further processed for in-gel digestion as described
in Gazdhar et al.44 An aliquot of 5 μl peptide extract was analyzed by LC-
MS/MS on an EASY-nLC1000 chromatograph connected to a QExactive HF
mass spectrometer (ThermoFisher Scientiﬁc) using a Pepmap100 Trap C18
300mm× 5mm (Thermo Fisher Scientiﬁc) and a C18 separation column
(3 μm, 100 Å, 75 μm× 15 cm, Nikkyo Technos, Tokyo, Japan) by applying a
40min gradient as previously described.45 LC-MS/MS data was processed
with MaxQuant (version 1.5.4.1) using default settings for peak detection,
strict trypsin cleavage rule allowing for upto three missed cleavages,
variable oxidation on methionine, deamidation of asparagine and
glutamine, and acetylation of protein N-termini with strict carbamido-
methylation of cysteines. Match between runs was used within each
sample group with a retention time window of 1min. The fragment
spectra were interpreted with the SwissProt Homo sapiens database
(version 2016_04) accepting only protein identiﬁcations with at least two
razor peptides at a 1% false discovery rate (FDR) cutoff.
For MS data analysis, peptide feature intensities were group-wise
median normalized and the intensities of the three most intense peptides
summed to the protein intensity. When a group had at least one positive
identiﬁcation, missing values were imputed from the low end of the LOG2
transformed intensity distribution from each individual sample using
Perseus (version 1.5.5.3) as suggested by Lazar et al.46 Proteins identiﬁed in
any of the three platelet controls were not included for pairwise Students
T-tests and a multi sample ANOVA tests, applying a permutation-based
FDR of 1% as an acceptation criteria for differentially expressed proteins
and to correct for multiple testing. Cellular function and location was
deﬁned using the Ingenuity Pathway Analysis (Qiagen). Evaluation of
overrepresented GO biological processes (complete) of proteins was
performed using Panther (www.pantherdb.org) and a Fisher’s Exact with
FDR multiple test correction. To display protein interactions selected
proteins were uploaded into String database (www.string-db.og) and
evaluated using Cytoscape (www.cytoscape.org).
hPBMC migration towards hMSC CM
Heparinized human peripheral blood was obtained from healthy donors (n
= 3) after informed written consent approved by the cantonal ethics
committee Zurich, Switzerland (KEK-ZH-2014-0430). Human peripheral
blood mononuclear cells (hPBMCs) were isolated according to standard
protocols by ﬁcoll density gradient centrifugation (Histopaque-1077;
Sigma, Switzerland). Migration of 3 × 106 hPBMCs in 300 μl basal medium
supplemented with 0.5% fetal calf serum (FCS) (Sigma, Switzerland)
towards the lower compartment containing either (I) 0.1 ml hMSC CM+
0.5% FCS (n= 5 per tissue source), (II) basal medium+ 0.5% FCS or (III)
5 ng/ml monocyte chemoattractant protein 1 (MCP-1)+ 0.5% FCS, was
evaluated through a PET membrane with 3 μm pores (Corning, USA) after
3 h. The number of migrated cells was deﬁned by counting cells over 1 min
on a FACSCanto II (BD Bioscience, USA). Monocyte subpopulations were
differentiated by staining with CD14, CD16, and propidium iodide (PI)
(supplementary Table S2; supplementary Fig. S13).
Thp-1/hMSC CM co-incubation
The monocyte phenotype after co-incubation with hMSC CM was analyzed
using the human monocytic leukemia cell line (Thp-1; Sigma, Switzerland).
Thp-1 cells were cultured in suspension using xVivo15 medium (Lonza,
Switzerland) and the medium was changed every 2–3 days. Thp-1 cells
were co-incubated for 16 h with either (I) hMSC CM (n= 5 per hMSC
group), (II) xVivo15 (n= 5) or (III) basal DMEM (n= 5). 0.2 ml hMSC CM
diluted 1:3 in basal DMEM was used per 100’000 Thp-1. After co-
incubation, ﬂoating and attached Thp-1 were harvested using Accutase
and stained 20min at 4 °C with CD11b, CD14, CD16, CD36, and SRA-I
(supplementary Table S2). All events were acquired using a LSR Fortessa
and the data sets were analyzed by FlowJo software gating viable and
single cells (for gating strategy see supplementary Fig. S13). Bidimensional
t-SNE maps were generated from multidimensional ﬂow cytometry data
(all events included) and PhenoGraph algorithm employed.
In vivo matrigel plug assay
The in vivo pro-angiogenic potential of hMSC CM was assessed performing
the Matrigel plug assay in C57BL/l mice (female, 7-week-old) divided into
four groups: control (n= 5; basal medium), hADSC CM (n= 5), hBMSC CM
(n= 5) and hWJSC CM (n= 5). For each condition 0.2 ml of medium was
mixed with 0.3 ml phenol red-free, growth factor reduced basement
membrane matrix (Corning, USA). Media were injected subcutaneously
into the left and right dorsal ﬂank of mice (n= 10 per group). After 14 days,
mice were sacriﬁced and the matrigel plugs were harvested. Matrigels
were analyzed macroscopically and histologically. All animal experiments
were approved by the Cantonal Ethics Committee (State Veterinary Ofﬁce
of the Canton of Zurich, Switzerland; No. 105/2016).
HUVEC/hMSC co-incubation
Endothelial cells were harvested from human umbilical cords following
written informed consent of the patients approved by the cantonal ethics
committee Zurich, Switzerland (KEK-ZH-2009-0095). Brieﬂy, HUVEC were
dissociated from the venous lumen by incubating a collagenase solution
(2mg/ml collagenase type A, Roche Diagnostics GmBH, Switzerland) for
30min in a humidiﬁed incubator at 37 °C and obtained in endothelial
growth medium (EGM-2; Lonza, Switzerland).
After several passages, HUVEC were starved in endothelial basal medium
(EBM-2; Lonza, Switzerland) with 1% FCS for 4 h and co-incubated for 16 h
with either (I) hMSC CM+ 0.5% FCS (n= 5 per hMSC group), (II) EGM-2 (n
= 5) or (III) basal DMEM+ 0.5% FCS (n= 5). 0.2 ml hMSC CM diluted 1:3 in
basal DMEM was used per 100,000 HUVEC. Harvested HUVEC were stained
20min at 4 °C with the following surface antibodies CD31, CD105, CD144,
and CD202b (supplementary Table S2). 50,000 events acquired on a LSR
Fortessa were analyzed by FlowJo software gating viable and single cells
(for gating strategy see supplementary Fig. S13). Bidimensional t-SNE maps
were generated (5000 events) and PhenoGraph algorithm applied.
Statistical analysis
Quantitative data are presented as mean ± standard deviation (GraphPad
Prism; Graph Pad Software, Inc.). For statistical comparison One-Way
ANOVA with Tukey multiple comparison test was used. Saphiro-Wilk
normality test proved that the datasets were normally distributed. Bar
graphs present Mean ± Standard Deviation (s.d.). P-values < 0.05 were
considered statistically signiﬁcant (*p < 0.05, **p < 0.01, ***p < 0.001).
Reporting Summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
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